Elevance Health, Inc. (LON:0HG8)
345.06
+1.11 (0.32%)
At close: Dec 19, 2025
Elevance Health Revenue
Elevance Health had revenue of $50.09B USD in the quarter ending September 30, 2025, with 12.00% growth. This brings the company's revenue in the last twelve months to $193.26B, up 11.93% year-over-year. In the year 2024, Elevance Health had annual revenue of $175.20B with 2.93% growth.
Revenue (ttm)
$193.26B
Revenue Growth
+11.93%
P/S Ratio
0.39
Revenue / Employee
$1.85M
Employees
104,200
Market Cap
56.61B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 175.20B | 5.00B | 2.93% |
| Dec 31, 2023 | 170.21B | 14.55B | 9.35% |
| Dec 31, 2022 | 155.66B | 18.72B | 13.67% |
| Dec 31, 2021 | 136.94B | 16.14B | 13.36% |
| Dec 31, 2020 | 120.81B | 17.67B | 17.13% |
| Dec 31, 2019 | 103.14B | 11.80B | 12.92% |
| Dec 31, 2018 | 91.34B | 2.28B | 2.56% |
| Dec 31, 2017 | 89.06B | 4.87B | 5.78% |
| Dec 31, 2016 | 84.19B | 5.79B | 7.38% |
| Dec 31, 2015 | 78.40B | 5.38B | 7.37% |
| Dec 31, 2014 | 73.02B | 2.83B | 4.03% |
| Dec 31, 2013 | 70.19B | 9.68B | 15.99% |
| Dec 31, 2012 | 60.51B | 648.80M | 1.08% |
| Dec 31, 2011 | 59.87B | 2.12B | 3.68% |
| Dec 31, 2010 | 57.74B | -3.00B | -4.94% |
| Dec 31, 2009 | 60.74B | -839.20M | -1.36% |
| Dec 31, 2008 | 61.58B | 1.42B | 2.37% |
| Dec 31, 2007 | 60.16B | 3.98B | 7.08% |
| Dec 31, 2006 | 56.18B | 12.19B | 27.71% |
| Dec 31, 2005 | 43.99B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
Elevance Health News
- 7 days ago - ELV Quantitative Stock Analysis - Martin Zweig - Nasdaq
- 8 days ago - Elevance Health Reflects On The Changed Role of Health Plans - Business Wire
- 8 days ago - AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries - Business Wire
- 9 days ago - Elevance Health Breaks Above 200-Day Moving Average - Bullish for ELV - Nasdaq
- 9 days ago - Noteworthy Thursday Option Activity: ELV, ZION, HUT - Nasdaq
- 9 days ago - Guru Fundamental Report for ELV - Martin Zweig - Nasdaq
- 10 days ago - Elevance Health (ELV) Appoints Amy W. Schulman as Independent Director - GuruFocus
- 10 days ago - Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence - Business Wire